ENTERPRISE AI ANALYSIS
AI-assisted ultrasonic system for non-invasive glucose classification in whole blood
This research explores a novel non-invasive approach for glucose monitoring using an 80 MHz high-frequency ultrasound (HFU) transducer combined with a convolutional neural network (CNN). The system analyzes time-frequency representations of ultrasonic signals from whole blood to classify glucose concentrations. Despite inherent challenges like signal heterogeneity and noise in whole blood, the system achieved approximately 68% multi-class accuracy across various glucose levels. Notably, for binary classification (diagnosing hypoglycemia/hyperglycemia), accuracy reached over 90%. This AI-driven ultrasonic method shows promise for continuous, non-invasive glucose assessment, offering a potential alternative to current invasive monitoring methods and supporting improved diabetes management.
Impact at a Glance
Our AI-driven solutions deliver tangible benefits across key operational metrics.
68%
Multi-class Accuracy (Overall)
90%
Binary Classification Accuracy (Hypo/Hyper)
80 MHz
HFU Transducer Frequency
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
The study utilized an 80 MHz high-frequency ultrasound (HFU) transducer to collect reflection signals from whole blood samples with varying glucose concentrations. These signals were then transformed into time-frequency representations using Short-Time Fourier Transform (STFT) and fed into various Convolutional Neural Network (CNN) architectures (VGGNet, InceptionNet, ResNet, EfficientNet) for classification. The approach aimed to evaluate the robustness of CNNs in handling noisy and heterogeneous whole blood signals without additional filtering.
The system achieved an approximate 68% multi-class accuracy across six distinct glucose levels (0, 50, 100, 150, 200, 250 mg/dL). InceptionNet and ResNet demonstrated the highest generalization performance among the models. When reframed as a binary classification task (hypoglycemia/hyperglycemia using 150 mg/dL threshold), accuracy and F1-scores improved significantly to over 90%, indicating strong potential for detecting critical glucose states.
This AI-assisted ultrasonic system presents a promising non-invasive alternative for continuous glucose monitoring (CGM). Its ability to classify glucose levels in whole blood, especially for critical diagnostic thresholds, supports improved diabetes management. Future work includes reducing signal noise, expanding dataset size, and validating the method under dynamic flow conditions and in biological samples to enhance clinical applicability and achieve ISO standards compliance for continuous glucose estimation.
68%
Overall Multi-Class Accuracy
Enterprise Process Flow
HFU Signal Acquisition (80 MHz)
→
Time-Frequency Transformation (STFT)
→
CNN Model Training (Glucose Classification)
→
Non-invasive Glucose Assessment
| Model | Accuracy | Precision | Recall | F1 Score |
|---|---|---|---|---|
| InceptionNet | 0.6799 | 0.6925 | 0.6799 | 0.6861 |
| ResNet | 0.6837 | 0.6874 | 0.6837 | 0.6855 |
| VGGNet | 0.6504 | 0.6524 | 0.6504 | 0.6514 |
| EfficientNet | 0.6575 | 0.6586 | 0.6575 | 0.6581 |
90%+
Binary Classification Accuracy (Hypoglycemia/Hyperglycemia)
Clinical Translation Potential
The study highlights the potential for this AI-driven ultrasonic system as a non-invasive continuous glucose monitoring (CGM) solution. Current CGM devices are invasive and have inherent time lags. This technology could address these limitations.
Outcome: While the current multi-class accuracy is around 68%, the binary classification accuracy (detecting critical thresholds like hypoglycemia/hyperglycemia) exceeds 90%. This indicates strong clinical relevance for immediate diagnostic decision-making.
Key Learnings:
- Noise reduction and larger, more diverse datasets are crucial for improving multi-class accuracy and generalization.
- Further validation in dynamic flow conditions and real biological samples is required for clinical adoption.
- The system's contact-based, non-invasive nature is a significant advantage over existing methods.
Advanced ROI Calculator
Estimate the potential operational savings and efficiency gains for your enterprise by integrating AI-assisted non-invasive monitoring solutions.
Implementation Roadmap
A phased approach ensures seamless integration and maximum impact.
Phase 1: Feasibility & Pilot Study
Conduct a preliminary study with a limited dataset to validate the AI model's performance on your specific use case. Focus on data acquisition protocols and initial model training.
Phase 2: Data Expansion & Model Refinement
Expand the dataset to include diverse biological samples and dynamic conditions. Refine CNN architectures and noise reduction techniques to improve accuracy and generalization.
Phase 3: Clinical Validation & Integration
Perform rigorous clinical trials to validate the system against ISO standards. Integrate the AI-assisted ultrasonic system into existing healthcare infrastructure or develop standalone devices.
Phase 4: Scalable Deployment & Continuous Improvement
Deploy the solution across clinical settings or for home-based monitoring. Establish feedback loops for continuous model improvement and adaptation to new data.
Ready to Transform Diabetes Management?
Explore how our AI-assisted ultrasonic solutions can integrate into your healthcare enterprise.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat